| Today's Big NewsNov 16, 2022 |
| By Paige Minemyer LAS VEGAS—Optum Rx is planning to add up to three biosimilar drugs to its formulary to compete directly with AbbVie's Humira, which accounts for massive pharmacy spend each year. |
|
|
|
By Zoey Becker While there is certainly progress being made across the industry, there’s plenty of more work to do to improve access to medicines in low- and middle-income countries, according to the Access to Medicine Foundation's new report this week. |
By James Waldron Novartis has halted a phase 1 trial of its CD73 antagonist due to a low likelihood of efficacy, although the Big Pharma will continue to explore the therapy’s potential as part of a combo regimen. |
By Conor Hale Illumina has begun to lay off about 5% of its global workforce spanning more than 9,100 people, a move the DNA sequencing giant described as “proactively realigning” its core operations in the face of broader macroeconomic difficulties. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now. 
|
|
By Andrea Park For the second time this year, Pear Therapeutics is laying off employees to cut costs and extend its cash runway through 2023. |
By Heather Landi Amazon has rolled out a new virtual medical clinic that aims to treat common conditions like allergies, hair loss and skin conditions. |
By Kevin Dunleavy The hits just keep on coming for Indian manufacturing giant Lupin as it continues to run afoul of the FDA. In a regulatory filing on Oct. 30 with the Bombay Stock Exchange, the drugmaker said it received a Form 483 notice from the FDA citing problems at its injectables facility in Nagpur. It was the third time in a span of five weeks that Lupin revealed a compliance reprimand from the FDA in a regulatory filing. |
By Max Bayer Gene therapy biotech Kriya Therapeutics is continuing its acquisition streak to build out a pipeline, this time with a focus on the brain. The North Carolina-based biotech is buying Redpin Therapeutics to expand, acquiring treatments for epilepsy and trigeminal neuralgia. There were no dollar figures included in Wednesday’s deal announcement and a press contact for Kriya said financial details weren’t being disclosed. |
By Paige Minemyer LAS VEGAS—Uber Health is expanding its platforms into the employer market, the company announced this week at the HLTH conference. |
By Fraiser Kansteiner Kindeva will merge with ex-Pfizer subsidiary Meridian Medical Technologies to spawn a globetrotting drug-device contract development and manufacturing organization. Both companies have been in the drug delivery game for decades, but Meridian's reputation took a hit after multiple EpiPen entanglements. |
By Nick Paul Taylor NextCure has found a new use for its anti-B7-H4 antibody NC762. By partnering with Korea’s LegoChem Biosciences, the biotech plans to aim an antibody-drug conjugate at the oncology target and join an R&D race featuring AstraZeneca, Mersana Therapeutics and Seagen. |
By Conor Hale In its response, Twist pointed investors to tune into its earnings call scheduled for this Friday, Nov. 18, covering its 2022 fiscal year. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 29, 2022 | 2pm ET / 11am PT Process development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise in a field that is very dynamic and accelerating fast. Outsourcing gives you direct access to infrastructure, experience, and a team who has done this before and can quickly generate meaningful data taking the guesswork out of process development. Register now. 
|
|
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
